Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, Pace Ally on Mesothelioma Test Marketing, Services

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pace Claims Service will provide educational and marketing services on behalf of Rosetta Genomics for its miRview meso diagnostic test for mesothelioma under an exclusive marketing deal announced today.

Pace will provide its services to defendants and insurers involved in mesothelioma legal cases, and market miRview meso as a tool for cancer diagnosis, "thereby potentially saving defendants who might otherwise pay millions to claimants who were misdiagnosed with mesothelioma," Rosetta said in a statement.

Financial and other terms of the deal were not disclosed.

Citing statistics from the World Health Organization, Rosetta said that between the years 2000 and 2004 about 2,500 Americans died from mesothelioma in the US. During the same period there were 27,000 mesothelioma deaths outside the US.

The potential market for miRview meso is more than 2,000 new claims and more than 8,000 claims currently pending in the US, said Rosetta.

"This marketing agreement expands our commercial strategy for the miRview product line and augments our recently launched sales efforts in the US aimed at marketing our diagnostic products to pathologists and oncologists at leading cancer institutions and clinics," Rosetta President and CEO Kenneth Berlin said.

Pace is a wholly owned subsidiary of Navigant Consulting and provides asbestos claims administration. Exposure to asbestos is a leading risk factor in developing mesothelioma.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.